Wound Healing Breakthrough: Can mRNA Technology Accelerate Recovery?
"New research explores how modified messenger RNA could revolutionize skin repair, offering faster and more effective treatments for wounds."
Wound healing is a complex process involving multiple stages, from inflammation to tissue remodeling. Growth factors play a crucial role in this process, but their effectiveness in chronic wounds is often limited due to poor bioavailability and rapid degradation. This has led researchers to explore innovative strategies to enhance growth factor delivery and efficacy.
One promising approach involves messenger RNA (mRNA) therapy. Unlike gene therapy, which permanently alters a cell's DNA, mRNA therapy offers a transient effect, potentially increasing growth factor concentration in the wound area without long-term genetic modifications. This could be particularly beneficial in preventing complications like tumorigenesis.
Recent research has focused on using modified mRNA to deliver keratinocyte growth factor (KGF), a key protein involved in skin repair. By transfecting cells with KGF-encoding mRNA, scientists aim to accelerate cell proliferation and migration, ultimately promoting faster and more effective wound healing.
VEGF-A mRNA and Wound Repair
A population pharmacokinetic and pharmacodynamic model of AZD8601, an mRNA designed to produce vascular endothelial growth factor A (VEGF-A), found that it could produce a sustained, dose-dependent acceleration of wound healing in preclinical studies. The model linked findings across studies and predicted clinically meaningful scenarios, including the possibility of less frequent delivery of larger doses. A separate murine full-thickness excisional wound study reported that topical lipid nanoparticle (LNP)-delivered VEGF-A mRNA promoted angiogenesis and wound healing, describing the approach as non-invasive. These findings are preclinical and do not establish a clinical impact in people. (Reference URL 1; Reference URL 2)
Dressings and the Case for Active Therapies
Wound dressings can provide a defensive barrier that supports healing and helps prevent further infection during recovery. The review on nucleic acid-based therapeutics reports that traditionally used gauzes, whether plant-derived or synthetic, are not suitable for active healing, particularly for serious or recurring skin wounds. Separately, preclinical studies of mRNA-loaded nanocarriers report potential to accelerate healing by stimulating angiogenesis and epidermal cell migration, and to increase collagen and elastin synthesis. These findings describe research potential rather than established clinical effectiveness. (Reference URL 1; Reference URL 2)
From Wound-History Reviews to RNA Research
The historical chapter cites Leaper’s “History of wound healing,” published in 1998 in *Wounds: Biology and Management*, and includes Ambroise Paré in its discussion of the development of surgery in France. More recent research directions include reviews of m6A RNA methylation, which examine its roles and mechanisms in wound healing and scars. A review of noncoding RNAs describes the field as rapidly expanding and points to improving technologies for enhancing or suppressing target noncoding RNAs in vivo as a basis for possible future therapies. (Reference URL 1; Reference URL 2)
KGF-mRNA: A New Frontier in Wound Healing
The study published in Nucleic Acid Therapeutics, details how researchers developed a modified KGF messenger RNA (mRNA) to improve wound healing. The approach centers around leveraging the natural healing properties of keratinocyte growth factor (KGF), which stimulates cell proliferation and movement, critical for effective skin repair.
- Enhanced KGF Production: Cells transfected with KGF-mRNA showed a significant increase in KGF protein release.
- Accelerated Re-epithelialization: The increased KGF levels led to markedly improved re-epithelialization in the scratch assays, indicating faster wound closure.
- Temporary Effect: Unlike gene therapy, mRNA's effects are temporary, reducing risks associated with permanent genetic alterations.
- Targeted Delivery: This method allows for a localized increase in growth factor expression directly in the treated area.
Candidates and Growth-Factor Pathways
A qualitative review of scratch-assay research on keloid scars lists several investigated candidates, including FKBP10 knockdown, inhibitors of p38, JNK, and NFκB, an anti-collagen VI 3C4 antibody, Hsp27 siRNA, and a miR-34a mimic. A separate biomaterials paper reports that fibroblast growth factor 7 (FGF-7), formerly called keratinocyte growth factor (KGF), was incorporated into a hydrogel and describes it as a strong inducer of keratinocyte proliferation. Another review says KGF stimulates keratinocyte multiplication and migration and induces cell proliferation and motility. These sources describe research candidates and biological effects, not established clinical treatments. (Reference URL 1; Reference URL 2)
Evidence Gaps and Questions of Risk
The supplied review on potential health risks of mRNA-based vaccine therapy notes that synthetic mRNA therapeutics were proposed more than 30 years ago and that an mRNA platform has been used at massive scale in COVID-19 public-health efforts. The available source excerpt does not specify particular risks or establish how vaccine findings apply to wound-healing therapies. The wound-healing article describes mRNA therapy as transient and says it may raise growth-factor concentrations locally without permanently changing cellular DNA, potentially helping prevent complications such as tumorigenesis. That proposed benefit is not, in the supplied material, evidence that the risk has been eliminated. (Reference URL 1; Reference URL 2)
Regulating Protein Production: miRNAs and mRNA
The chronic-wound review explains that microRNAs (miRNAs) regulate protein production by blocking translation or degrading mRNA. A skin-wound review describes miRNAs as regulators of biological processes essential for wound healing and frames miRNA-based therapy and diagnosis as goals that research may help advance. Together, these sources describe miRNA regulation of mRNA and the prospect of targeting miRNAs as a research direction; they do not provide a direct comparison of miRNA-based interventions with therapeutic mRNA delivery. (Reference URL 1; Reference URL 2)
The Future of Wound Care: mRNA and Beyond
This research opens new avenues for wound treatment. The use of mRNA to deliver growth factors offers a controlled and temporary approach, potentially overcoming the limitations of traditional methods.
Exosomal mRNA as a Research Lead
A 2026 study reports selective mRNA enrichment in exosomes derived from umbilical cord mesenchymal stem cells (UCMSC-derived EXs). Its authors highlight the exosomes’ promising therapeutic potential in cutaneous wound healing. This is a research finding and potential, rather than evidence of demonstrated therapeutic benefit in patients. nature.com
Modification and Delivery in Regenerative Medicine
A 2025 review discusses the potential of mRNA drugs in regenerative medicine, focusing on therapeutic mRNA modification and delivery carriers. The supplied excerpt identifies these as key processes but does not specify particular modifications, carriers, or clinical outcomes. It presents mRNA therapy as a developing area of regenerative-medicine research. onlinelibrary.wiley.com
Skin Grafting and Cellular Aging
The cited study reports that applying an autologous human-skin-cell-suspension (hSCS) requires less donor skin than split-thickness skin grafting (STSG) without compromising healing capacity. It also notes that impaired function and replicative ability of senescent cutaneous cells in aging skin affect healing. The study identifies telomere erosion and DNA damage as major determinants of senescence and examines telomerase mRNA in relation to human skin engraftment for wound healing. pubmed.ncbi.nlm.nih.gov
While these findings are promising, further research is needed. Future studies should focus on in vivo testing to confirm the effectiveness and safety of KGF-mRNA therapy in living organisms. Additionally, refining mRNA delivery techniques and exploring combinations with other growth factors could further enhance wound healing outcomes.
The potential of mRNA therapy extends beyond wound care. This technology could revolutionize treatments for various conditions, from tissue regeneration to cancer therapy, marking a significant step forward in regenerative medicine.